event
Á¦¸ñ BSC-1401(Immuno-Oncology)
ÀÛ¼ºÀÚ bisichem
ÀÛ¼ºÀÏÀÚ 2021-04-08

BiSiChem is developing TGF-¥â inhibitors as a candidate for solid tumors and/or immunotherapy

and applied for the PCT international patent in 2020.

 
TGF-¥â Inhibitor relates to a series of substituted heterocyclic compounds which are inhibitors

of the transforming growth factor-¥â (TGF-¥â) type I receptor (ALK5) and/or the activin type I receptor (ALK4).

The inhibitor plays a key role in improving the surrounding environment to ensure that immune cells attack cancer cells.

 

In normal cells, TGF-¥â plays a crucial role in the maintenance of cell homeostasis and organ formation,

including cell growth & death, differentiation, immunity and epithelial-mesenchymal transition(EMT)

in various biological processes.

 
However, abnormal signal transduction of TGF-¥â causes life-threatening diseases such as cancer, fibrosis,

NASH, and diabetes. Especially in the tumor micro environment, it suppresses immunity, promotes cancer cell metastasis,

and induces anti-cancer drugs resistance.